Key findings
- Thresholds differ. South Asian adults reach the type 2 diabetes risk of a white adult with a BMI of 30 at a BMI of 23.9.1
- Life stage differs. The average age of menopause in India is 46.2 years, compared with about 51 in Western countries.3
- Climate performance is product-specific. In Thailand, 58% of women using an estradiol patch had unacceptable skin reactions, against none with a gel, and one patch brand lost a third of its estradiol after a month at 35°C.17,5
- Regulators recognise ethnic factors. International guidance has addressed how they affect a medicine's effect since 1998, and India may require local trials for new drugs approved abroad.7,8
The common thread: whether a women's health product will work in Asia depends on factors that are measurable but rarely measured before launch.
Market entry is decided on desk research. Products succeed or fail in real conditions.
Companies typically decide whether to enter an Asian market using market reports, competitor databases, regulatory summaries and, increasingly, AI-generated research. These sources describe a market. They do not show how a specific product performs with the women who will use it, in their climate, health system and daily life.
The evidence below shows three areas where that difference is documented in published research: metabolic risk, menopause, and product performance in heat. A fourth area, regulation, shows that authorities already treat population differences as a real factor.
Same disease, different thresholds
In 2004, a WHO expert consultation reviewed evidence on body mass index in Asian populations. It found that the proportion of Asian people at high risk of type 2 diabetes and cardiovascular disease is substantial at BMIs below the standard overweight cut-off of 25, with the BMI at which risk is observed ranging from 22 to 25 in different Asian populations. It identified additional public health action points at 23 and 27.5.2
A 2021 population-based cohort study of 1,472,819 adults in England quantified the difference for type 2 diabetes. The BMI associated with the same diabetes risk as a BMI of 30 in white adults was:1
| Population | Equivalent BMI |
|---|---|
| White | 30.0 |
| Black | 28.2 |
| Chinese | 27.0 |
| Arab | 26.8 |
| South Asian | 23.9 |
Source: Caleyachetty et al., The Lancet Diabetes & Endocrinology, 2021.
The pattern extends to women's health. A large clinical database of indigenous South Asian women with polycystic ovary syndrome found greater odds of central obesity among young women with PCOS, and describes South Asians as having a greater propensity to insulin resistance and metabolic syndrome. The authors' earlier work found that migrant South Asian women with PCOS had more severe symptoms at a younger age, with greater insulin resistance, than white European women.14
Products affected
- Risk scores and screening algorithms
- PCOS and gestational diabetes tools
- Metabolic and weight-related therapies
- Digital health apps with risk alerts
What to test before launch
- Whether thresholds and algorithms hold for the target population
- How clinicians apply the product in practice
- How women understand the risk messaging
Same life stage, different timing and symptoms
A pan-India survey by the Indian Menopause Society, published in the Journal of Mid-life Health in 2016, found an average age of menopause of 46.2 years, "much less than their Western counterparts (51 years)".3 With the number of Indian women aged 45 and over projected at around 400 million in 2026, this is a large population reaching menopause earlier than the Western reference point many products are designed around.10
Symptom profiles also differ. The US Study of Women's Health Across the Nation (SWAN), which followed women from several ethnic groups, found that hot flash trajectories vary by ethnicity, with Chinese women less likely than others to experience persistently high hot flashes.4
Products affected
- Hormone therapies and non-hormonal treatments
- Menopause diagnostics and tracking apps
- Positioning, claims and target age
What to test before launch
- Which symptoms and needs matter most to women
- When and where women seek care, and from whom
- Positioning and claims with clinicians and women
A product that works in London may not work in Mumbai
Hormone patches are a useful example, because they are an established, successful product in Western markets that depends on skin, sweat and temperature to work.
A successful product at home
Patches are widely used in the West. In the UK, demand for one HRT patch brand in 2019 had already overtaken demand for the whole of 2018 within months, contributing to national shortages.22 In the US, 10.6% of women aged 15 to 44 who have had sex have used a contraceptive patch at some point.21
Adhesion and skin reactions are known weak points
NHS guidance for pharmacists states that "adhesion issues with transdermal patches can be common, particularly in hot weather", and that the most common skin reactions are irritant contact dermatitis.19 The US FDA notes that adhesion performance affects both safety and effectiveness: a patch that lifts or falls off can under-dose the patient, and a detached patch can expose a partner or child to the drug.20
Successful patches were adapted
Patch design has changed to address these problems. In a randomised crossover trial of 82 women who had previously stopped patch therapy because of skin reactions, 26 discontinued an older reservoir patch, compared with 4 who discontinued a matrix patch, where the hormone is dissolved in the adhesive itself.16 Adoption in the West followed products that were adjusted to how women actually wear them.
What the evidence shows in hot, humid climates
| Finding | Setting | Result |
|---|---|---|
| Skin reactions with an estradiol patch vs gel | Thai postmenopausal women | 58% vs 0% |
| Imperfect adhesion of adhesive skin-test strips | 420 patients, Bangkok, 2018–19 | 28% |
| Estradiol lost by one patch brand after a month | Storage at 35°C | −33% |
| Detachment of a contraceptive patch | Manufacturer studies incl. heat and humidity | 4.7% |
Sources: Chompootaweep et al.; Kumpangsin et al., 2021; Ankarberg-Lindgren et al., 2019; Galzote et al., 2017.
In Thailand, 58% of postmenopausal women using an estradiol patch had unacceptable skin reactions, including itching, rash and residual pigmentation, while none had reactions with an estradiol gel that gave the same clinical benefit. The authors concluded that combining an adhesive, occlusive patch with a high estradiol concentration on a small skin area was not appropriate in a hot, humid climate.17 This is an older study of an early patch design, but it shows the kind of failure that only appears in the target climate.
A 2021 study at Siriraj Hospital in Bangkok followed 420 patients wearing adhesive patch-test strips on their skin. 28.3% had imperfect adhesion, significantly linked to heavy sweating and testing in the rainy season.18 These were diagnostic skin-test strips rather than hormone patches, but they show how sweat and season affect anything that must stay on the skin in a tropical climate.
Heat also affects the drug itself. When four estradiol patch brands were stored at 35°C for a month, three stayed stable, but one lost 33% of its estradiol in a sealed pouch, and the authors described it as "not stable for storage in a hot climate".5 The US FDA lists the impact of heat on drug delivery among the special considerations for transdermal products.15
Not every patch fails. Manufacturer studies of one contraceptive patch reported that adhesion did not differ with heat, humidity or exercise, with a detachment rate of 4.7%.6 That is the point: performance is product-specific, and the only way to know is to test the specific product in the specific conditions.
Will women use it?
Uptake of hormone therapy in India is low. According to a 2023 report by Elda Health, a menopause care provider, based on more than 25,000 of its customers, about 20% of women were recommended hormone therapy and 10% chose to take it after counselling and testing.23 This is company data rather than a national survey, but it suggests that acceptance, not only performance, has to be tested.
What might fail
- Skin reactions under occlusion in heat
- Detachment with sweat and monsoon humidity
- Loss of potency in hot storage and supply chains
- Low acceptance compared with gels, tablets or local alternatives
What to test before launch
- Wear and adhesion trials across seasons, including the monsoon
- Skin tolerance with the target population
- Stability through realistic storage and distribution
- Acceptance and preference among women and clinicians
Regulators already treat population differences as real
The ICH E5 guideline, adopted in 1998 and applied by regulators including the US FDA and the European Medicines Agency, provides a framework for evaluating how ethnic factors affect a medicine's efficacy and safety. It distinguishes intrinsic factors, such as genetic polymorphism, age, sex, height and weight, from extrinsic factors linked to environment and culture, such as medical practice, diet, and exposure to pollution and sunshine. Where needed, a bridging study in the new region provides data to extrapolate foreign results.7
In India, under the New Drugs and Clinical Trials Rules 2019, local phase III studies may be required to show efficacy and safety in Indian patients for new drugs approved abroad. An August 2024 order waived local trials only for selected categories, such as orphan drugs and therapies with significant advances over current care, approved in the US, UK, EU, Japan, Australia or Canada.8
What this means for companies considering Asia
Each of these differences is measurable. None of them is visible in a market report. Together they mean that the most important questions about a product's fit in Asia can only be answered with evidence from the target market itself:
- Do the product's thresholds, claims and design fit the target population?
- Does it perform in local conditions, from storage to daily use?
- Will clinicians recommend it and women use it, at a price that works?
- What will regulators require, and how long will it take?
A structured market fit assessment answers these questions before a company commits to a launch, combining research with clinicians, buyers and women, real-world evaluation through laboratory and clinical partners, and a regulatory and commercial model.
How to read this brief
This brief summarises published research to illustrate why testing in the target market matters. Some studies were conducted in migrant or US populations rather than in India. The patch studies cover specific products, designs and conditions, some are older or from abstracts, and the Bangkok adhesion study used diagnostic skin-test strips rather than hormone patches; they should not be generalised to all products. Uptake figures from a single provider are company data, not a national survey. The case studies are based on published research. Regulatory information is a summary and should be confirmed with a regulatory specialist for any specific product.
Sources
- Caleyachetty R. et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. The Lancet Diabetes & Endocrinology, 2021. University of Warwick summary
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet, 2004. Abstract
- Indian Menopause Society. Age of menopause and determinants of menopause age: a PAN India survey. Journal of Mid-life Health, 2016;7(3):126–131. Record
- Tepper P.G. et al. Trajectory of hot flashes in the Study of Women's Health Across the Nation (SWAN). Menopause, 2016. Summary
- Ankarberg-Lindgren C. et al. Estradiol matrix patches for pubertal induction: stability of cut pieces at different temperatures. Endocrine Connections, 2019;8(4):360–366. Full text
- Galzote R.M., Rafie S., Teal R., Mody S.K. Transdermal delivery of combined hormonal contraception: a review of the current literature. International Journal of Women's Health, 2017;9:315–321. Full text
- ICH E5(R1). Ethnic factors in the acceptability of foreign clinical data. European Medicines Agency; US FDA guidance (PDF)
- SpicyIP. Of clinical trial waivers in India: the misses outweigh the hits, 2024. Article
- Grand View Research. Asia Pacific femtech market outlook. Report page
- Indian Journal of Medical Research. Natural menopause in India. PMC
- Gaudium IVF. Investor presentation, Q1 FY27. PDF
- Medical Dialogues. Medical device imports still at 70%, Parliament informed. Article
- Gavi. India launches nationwide HPV vaccination. Article
- Wijeyaratne C.N. et al. Phenotype and metabolic profile of South Asian women with polycystic ovary syndrome (PCOS). Human Reproduction, 2011;26(1):202–213. Full text
- US FDA. Transdermal and topical delivery systems: product development and quality considerations (draft guidance, 2019). FDA
- Ross D. et al. Randomised crossover comparison of skin irritation with two transdermal oestradiol patches. BMJ, 1997;315:288. Full text
- Chompootaweep S. et al. A comparative study of skin tolerance after using estradiol patch and gel in Thai postmenopausal women. Journal of Basic and Applied Pharmacology (abstract). Abstract
- Kumpangsin T. et al. Seasonal and other factors affecting patch testing integrity in a tropical climate country. Thai Journal of Dermatology, 2021;37(1):1–9. Article
- NHS Specialist Pharmacy Service. Managing problems when using transdermal patches, 2025. Guidance
- US FDA. Assessment of adhesion of topical and transdermal systems submitted in new drug applications (draft guidance, 2021). FDA
- US CDC. Key statistics from the National Survey of Family Growth, 2011–2015: contraceptive patch. CDC
- Pulse. HRT shortages to continue into next year, 2019. Article
- Elda Health. State of menopausal health in India, 2023, as reported by The Bio Startups. Article